Financial reports
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
13 Nov 23
10-Q
2023 Q2
Quarterly report
16 Aug 23
NT 10-Q
Notice of late quarterly filing
15 Aug 23
10-Q
2023 Q1
Quarterly report
12 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
12 Aug 22
10-Q
2022 Q1
Quarterly report
13 May 22
10-K
2021 FY
Annual report
30 Mar 22
Current reports
8-K
Other Events
18 Apr 24
8-K
Other Events
16 Apr 24
8-K
Unregistered Sales of Equity Securities
15 Apr 24
8-K
RenovoRx Announces $11.1 Million At Market Private Placement
9 Apr 24
8-K
Departure of Directors or Certain Officers
14 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Feb 24
8-K
Departure of Directors or Certain Officers
9 Feb 24
8-K
RenovoRx Closes $6.1 Million Private Placement
29 Jan 24
8-K
Other Events
2 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
18 Dec 23
Registration and prospectus
D
$15.00 mm in equity / options / securities to be acquired, sold $11.14 mm, 172 investors
22 Apr 24
S-3
Shelf registration
19 Apr 24
S-8
Registration of securities for employees
12 Apr 24
D
Exempt offering of security
9 Feb 24
424B3
Prospectus supplement
19 May 23
S-3
Shelf registration
12 May 23
424B5
Prospectus supplement for primary offering
3 Apr 23
S-8 POS
Registration of securities for employees (post-effective amendment)
31 Mar 23
S-8
Registration of securities for employees
31 Mar 23
424B3
Prospectus supplement
22 Nov 22
Proxies
Other
EFFECT
Notice of effectiveness
22 May 23
CORRESP
Correspondence with SEC
17 May 23
UPLOAD
Letter from SEC
16 May 23
EFFECT
Notice of effectiveness
22 Nov 22
EFFECT
Notice of effectiveness
22 Nov 22
CORRESP
Correspondence with SEC
18 Nov 22
CORRESP
Correspondence with SEC
18 Nov 22
UPLOAD
Letter from SEC
16 Nov 22
UPLOAD
Letter from SEC
16 Nov 22
EFFECT
Notice of effectiveness
26 Aug 21